Season 1
Exploring Treating Covid 19 Through Cell Signalling
In this interview Dr. Lorne Brown and Dr. John McMichaels speak about the clinical studies on COVID-19 with a new product called TML. It is a viral product built to work with cells signaling. TML works in a way that brings the body back into balance providing all the bodies mechanisms are there and available at the cellular level.
This product is not a cure but meant to catch the disease early so a person does not end up in the hospital.
Highlights
Start – Dr. John McMichael introduction
2:31 mins – Discussing clinical trial for COVID-19
4:00 mins – Discussing cell signalling and explaining how it works
6:17 mins – How resonant molecular signalling impacts disease and health
8:21 mins – Discussing being able to help ‘long haulers’
9:45 mins – Discussing severe reactions and being hospitalized
10:12 mins- Discussing TML with recurrent oral herpes infections
11:38 mins – Discussing other products in the works
12:53 mins- Discussing the mechanism for brain injury
15:00 mins – Discussing the mechanisms for anxiety and depression and creating the product
16:35 mins – Discussing micro-dosing and hormesis
19:18 mins – Discussing the success rate with the TML
20:09 mins – Discussing why it doesn’t work for everyone
22:05 mins – Discussing Phase 3 with TML and when it should be expected
24:28 mins – Mentioning beechtreelabs.com donations and investing
25:00 mins – Discussing continued research on anxiety and depression TML
25:14 mins – Discussing the material in products used and safety issues
29:11 mins – Discussing if you can take the product prophetically
30:08 mins – Closing off the interview with Dr. John McMichael
Hosts & Guests
Lorne Brown
John McMichael
Resources
About the Speaker
Dr. McMichael received his B.S. in Microbiology from the University of Maine and his Ph.D. from Oregon State University in Immunology and Virology, and did his post-doctoral work at the Wistar Institute in Philadelphia, PA. He developed the world’s first live-virus fish vaccines for use in fish populations, and is an Alzheimer’s disease pioneer, having licensed 30+ patents to Elan Corp. plc, to support their Alzheimer’s initiative. He now holds more than 200 patents worldwide. His experience also includes:
- Professor of Biology and Health Sciences, Edinboro University of Pennsylvania;
- General Manager for ImmunoTherapeutics, where he licensed a veterinary anti-inflammatory product to Eudomonics, Inc., which launched and continues to sell the product;
- Vice President of Molecular Rx, Inc., a biopharmaceutical company focused on products for managing inflammatory responses;
- Founder and President of Milkhaus Laboratory, Inc., a company now focused on botanical agents for nutraceutical use;
- Founder and President of The Institute for Therapeutic Discovery, a not-for-profit organization focusing on the interplay between biochemistry and biophysics in the course and management of health and disease.
